683 Capital Management LLC Takes $1.36 Million Position in Zura Bio Limited $ZURA

683 Capital Management LLC acquired a new stake in Zura Bio Limited (NASDAQ:ZURA) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 259,165 shares of the company’s stock, valued at approximately $1,358,000.

Other institutional investors have also recently bought and sold shares of the company. Allworth Financial LP purchased a new stake in Zura Bio in the fourth quarter valued at approximately $30,000. Scientech Research LLC purchased a new stake in Zura Bio in the third quarter valued at approximately $45,000. Dimensional Fund Advisors LP purchased a new stake in Zura Bio in the fourth quarter valued at approximately $123,000. Squarepoint Ops LLC purchased a new stake in Zura Bio in the third quarter valued at approximately $109,000. Finally, Qube Research & Technologies Ltd purchased a new stake in Zura Bio in the third quarter valued at approximately $138,000. 61.14% of the stock is currently owned by hedge funds and other institutional investors.

Zura Bio Stock Up 2.8%

ZURA opened at $3.62 on Thursday. Zura Bio Limited has a 52-week low of $1.00 and a 52-week high of $7.44. The company has a 50 day moving average of $4.66 and a two-hundred day moving average of $5.23. The company has a market cap of $343.47 million, a P/E ratio of -3.32 and a beta of 0.03.

Zura Bio (NASDAQ:ZURA) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.05). Research analysts anticipate that Zura Bio Limited will post -0.76 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ZURA has been the subject of a number of recent analyst reports. Chardan Capital boosted their target price on shares of Zura Bio from $10.00 to $11.00 and gave the company a “buy” rating in a report on Monday, March 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of Zura Bio in a report on Wednesday, April 8th. Finally, Oppenheimer lowered their target price on shares of Zura Bio from $16.00 to $15.00 and set an “outperform” rating for the company in a report on Friday, March 20th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Zura Bio currently has an average rating of “Moderate Buy” and a consensus target price of $10.75.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.